Key result
Oncostatin M neutralization restores cardiomyocyte mitochondrial bioenergetics and contractility in experimental fulminant myocarditis.
Why the study?
Fulminant myocarditis is an acute inflammatory cardiomyopathy with high risk of cardiogenic shock and poorly defined mechanism-based pharmacological targets.
Does targeting macrophage-derived oncostatin M (OSM) improve survival, cardiac function, and cardiomyocyte mitochondrial bioenergetics in experimental fulminant myocarditis?
Does targeting macrophage-derived oncostatin M (OSM) improve survival, cardiac function, and cardiomyocyte mitochondrial bioenergetics in experimental fulminant myocarditis?
Targeting the macrophage-to-cardiomyocyte OSM-OSMR signaling axis preserves mitochondrial and contractile function, offering a novel mechanism-based pharmacological target for acute inflammatory cardiac dysfunction.
Supports CCR2-mediated interactions as candidate targets in fulminant myocarditis; leaves open whether inhibition improves outcomes.
Background Fulminant myocarditis (FM) is an acute inflammatory cardiomyopathy with high risk of cardiogenic shock. Current management relies largely on circulatory support, while mechanism-based pharmacological targets remain poorly defined. Methods Cardiac CD45 + single-cell RNA sequencing, whole-heart single-nucleus RNA sequencing, ligand–target inference, spatial validation, and human plasma/myocardial analyses were integrated to define disease-associated cellular interactions. CCR2 + macrophage sorting, macrophage depletion, CVB3-stimulated BMDMs, transcription-factor perturbation, ChIP-qPCR, and promoter assays defined the source and regulation of OSM. OSM signaling was examined using recombinant OSM, OSM-neutralizing antibody, macrophage Osm knockdown, cardiomyocyte Osmr silencing, and STAT3/ERK1/2 inhibition, followed by transcriptomic, mitochondrial, contractile, and in vivo analyses. Results FM featured expansion of CCR2 + inflammatory macrophages, cardiomyocyte inflammatory/stress remodeling, and enhanced macrophage-to-cardiomyocyte OSM–OSMR signaling. Circulating OSM was increased in patients with FM and correlated with higher NT-proBNP and cTnI and lower LVEF. OSM was produced predominantly by CCR2 + macrophages and transcriptionally induced by IRF1 after CVB3 stimulation. Recombinant OSM aggravated mortality, systolic dysfunction, myocardial inflammation, and cardiac injury. In cardiomyocytes, OSM activated OSMR-dependent STAT3/ERK1/2 signaling and impaired mitochondrial bioenergetics, contractility, and Ca² + handling. OSM neutralization and macrophage Osm knockdown improved cardiomyocyte respiration and sarcomere shortening after exposure to CVB3-activated macrophage conditioned medium. In vivo, OSM neutralization improved survival, cardiac function, myocardial inflammation, mitochondrial integrity, and ATP content. Conclusion Macrophage OSM links inflammatory myeloid activation to cardiomyocyte mitochondrial and contractile failure in experimental FM. OSM–OSMR signaling is a candidate mechanism-based pharmacological target for acute inflammatory cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied Fulminant myocarditis. Targeting macrophage-derived oncostatin M (OSM neutralization) was evaluated on Mitochondrial bioenergetics, contractile function, survival, and cardiac function. In experimental fulminant myocarditis, macrophage-derived oncostatin M impairs cardiomyocyte mitochondrial bioenergetics and contractility, which are improved by OSM neutralization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: